Raymond James Financial Inc. Invests $2.43 Million in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Raymond James Financial Inc. acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 84,883 shares of the specialty pharmaceutical company's stock, valued at approximately $2,432,000. Raymond James Financial Inc. owned about 0.26% of Collegium Pharmaceutical as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Invesco Ltd. increased its holdings in shares of Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after purchasing an additional 289,335 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after purchasing an additional 5,480 shares during the last quarter. Royce & Associates LP grew its holdings in shares of Collegium Pharmaceutical by 11.0% in the 4th quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after acquiring an additional 33,674 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after buying an additional 175,892 shares in the last quarter.

Collegium Pharmaceutical Trading Up 2.2 %

Shares of Collegium Pharmaceutical stock traded up $0.59 on Friday, hitting $27.65. 185,299 shares of the company traded hands, compared to its average volume of 441,815. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock's 50 day moving average price is $28.19 and its 200-day moving average price is $30.43. The company has a market cap of $888.45 million, a PE ratio of 11.92 and a beta of 0.76. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Wall Street Analysts Forecast Growth

COLL has been the subject of several recent research reports. Piper Sandler reduced their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 977 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the transaction, the chief financial officer now owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This trade represents a 0.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now owns 108,137 shares in the company, valued at $3,081,904.50. This represents a 19.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is owned by insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.